Custom Advances in precision medicine and genomic sequencing

Date: This event took place on November 29, 2016

Custom webcast sponsor retains sole responsibility for content.

Watch on-demand

Next-generation sequencing platforms are opening up new opportunities in precision medicine by dramatically reducing the cost and time to access large volumes of genomic data.
This webcast will highlight innovative technologies being developed by companies in the field, and how they are laying the groundwork for novel therapeutics and diagnostics in areas such as oncology and rare diseases. The topics will include advanced bioinformatics and next-generation sequencing for pathogen detection, nanosensor technology for genome sequencing and healthcare diagnostics, molecular indexing technology for digital detection of single cells and cloud-based accelerated genomics analysis.

The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to hear the views of the speakers and to put your own questions to them.

BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.

Sponsored by

4 Logos

Speakers

  • Bharath Takulapalli, iNanoBio

    Bharath Takulapalli, iNanoBio

    Bharath Takulapalli is Founder & CEO of INanoBio. He is principal inventor of INanoBio nano-sensor technologies. He has authored multiple publications and patents in the areas of biosensors, nanotechnology, genome sequencing and proteomics. With doctoral training in chem-bio sensors, solid state electronics and material science, over the past twelve years he has worked on developing nano-bio technology solutions to personalized healthcare of the future. His current areas of focus are ultra-fast high-accuracy $100 whole genome sequencer and low cost point-of-care diagnostics. Dr. Takulapalli has a bachelor’s from IIT Madras India, and PhD from Arizona State University in Tempe.

  • Crystal R Icenhour, Aperiomics, Inc.

    Crystal R Icenhour, Aperiomics, Inc.

    In 2014, Crystal R Icenhour, PhD was recruited to serve as founding CEO of Aperiomics, Inc.  Aperiomics is a service laboratory specializing in harnessing the power of next-generation sequencing to improve world health.  She is also an adjunct assistant professor at Duke University Medical Center’s Division of Infectious Diseases in their Department of Medicine. Dr. Icenhour currently serves as Chairman of Virginia BIO and was chosen to participate in the SpringBoard Enterprises 2016 class of women-led companies.  She is a member of, Sigma Xi, Medical Mycology Society of the Americas, National Postdoctoral Association, and the American Society for Microbiology.

  • Hans Cobben, Bluebee

    Hans Cobben, Bluebee

    Hans Cobben is the CEO of Bluebee.  Hans is a serial entrepreneur, seasoned executive, investor and enabler for startups. He is a cofounder of multiple globally successful companies and has held senior executive roles at multinational corporations such as Alcatel Lucent, SunGard and SWIFT. He currently serves on a number of boards of directors and is an active seed investor in several early stage companies. His interest goes specifically to artificial intelligence, deep learning and high performance computing developments. Driven by his experience in deploying leading edge technology in complex application fields and by a strong believe in the potential of genomics, Hans joined Bluebee as an investor and CEO in 2013.

  • Jonathan Seaton, Becton Dickinson (BD)

    Jonathan Seaton, Becton Dickinson (BD)

    Jonathan Seaton is the Vice President of Strategy and Business Development, Life Sciences for Becton Dickinson (BD) and a frequent speaker at industry conferences, where he shares his insights on current challenges and future trends in genomics. Prior to BD, Jonathan held the role of Vice Director, Global Business Development for Roche Diagnostics, and has also worked in investment banking in Deutsche Bank Securities and financial advisory services in multiple companies, all focused in the life sciences industry, both in the US and the UK. Jonathan holds an MBA from the Said School of Business, University of Oxford, a MB ChB in Medicine from the University of Manchester and a BSc, Molecular Biology and Biochemistry from the University of Durham in the UK. Jonathan is passionate about driving strategy and new business models – such as translating the power of genomics into real-world results.

  • Raveena Bhambra, BioPharma Dealmakers

    Moderator: Raveena Bhambra, BioPharma Dealmakers

    Raveena Bhambra is the Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing. Previously she worked at a life sciences publisher producing dealmaking focused reports and prior to that worked as a Strategic Partnering Analyst.